Dr. Kim Discusses Detecting EGFR and KRAS Mutations from Cell-Free Plasma DNA of NSCLC Patients
У вашего броузера проблема в совместимости с HTML5
Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of improved and complete enrichment co-amplification at lower denaturation temperature method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients.